Yatiri Bio Inc. today announced the addition of Michael J. Kamdar, former CEO and President of Molecular Assemblies to the company’s strategic advisory board.

“We are honored and grateful to have Mike join our Advisory Board,” said CEO Pilgrim Jackson. “Mike’s leadership, knowledge, and commercial experiences are all attributes that Yatiri Bio can draw from.  We look forward to working with and integrating his wealth of technical and commercial experiences in establishing and growing our company.”

“I am very excited to work with Pilgrim and the Yatiri Bio team,” said Michael J. Kamdar. “The combination of the proteomics platform and AI capabilities coupled with the seasoned team at Yatiri Bio offers incredible potential for directing cancer therapies.”

Michael J. Kamdar is a seasoned life science & healthcare executive with over 30 years of international leadership experience.  He is an industry veteran that has done over $1B in business deals and raised more than $450M from venture firms and public markets.  Mr. Kamdar has led a multitude of life science and healthcare corporations, including Molecular Assemblies, Ciclofilin Pharmaceuticals, Genoa Pharmaceuticals, VentiRx Pharmaceuticals (a company he co-founded which was subsequently acquired by Celgene), Anadys Pharmaceuticals, and Agouron Pharmaceuticals (acquired by Pfizer).  He currently sits on the boards of Aeena Dx and Vault Pharma. For more information on Mr. Kamdar please visit https://www.linkedin.com/in/michael-kamdar-085a7aa/.